Critical Survey: ARS Pharmaceuticals (NASDAQ:SPRY) & Actinium Pharmaceuticals (NYSE:ATNM)

ARS Pharmaceuticals (NASDAQ:SPRY) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a breakdown of current recommendations for ARS Pharmaceuticals and Actinium Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	0	0	4	2	3.33
Actinium Pharmaceuticals	0	1	4	0	2.80

ARS Pharmaceuticals presently has a consensus target price of $24.00, indicating a potential upside of 65.98%. Actinium Pharmaceuticals has a consensus target price of $11.40, indicating a potential upside of 519.57%. Given Actinium Pharmaceuticals’ higher probable upside, analysts plainly believe Actinium Pharmaceuticals is more favorable than ARS Pharmaceuticals.

Volatility & Risk

ARS Pharmaceuticals has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Comparatively, Actinium Pharmaceuticals has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Earnings and Valuation

This table compares ARS Pharmaceuticals and Actinium Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$30,000.00	46,725.08	-$54.37 million	($0.52)	-27.81
Actinium Pharmaceuticals	$81,000.00	676.55	-$48.82 million	($1.71)	-1.08

Actinium Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Actinium Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 40.1% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares ARS Pharmaceuticals and Actinium Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	N/A	-19.77%	-19.26%
Actinium Pharmaceuticals	N/A	-101.69%	-48.91%

Summary

ARS Pharmaceuticals beats Actinium Pharmaceuticals on 9 of the 12 factors compared between the two stocks.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company’s research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.